An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of standard-of-care statin therapy, as compared with placebo. AZD0780 is an ...

HealthDay News — Combination lipid-lowering therapy (LLT) is associated with a greater reduction in low-density lipoprotein cholesterol (LDL-C) compared with statin monotherapy, according to a study ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

I have had cholesterol tests for the past 30 years with HDL readings that had a low of 68 mg/dL and a high of 117 mg/dL.

The largest analysis to examine the best way to lower levels of "bad" cholesterol in patients with blocked arteries shows ...

A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived ...